Contact
Let’s get in contact

Publications

Recombinant antibodies and recombinant proteins produced by evitria find applications in various research endeavors. On this page you will see a selected list of peer-reviewed publications that reference evitria.

We would appreciate hearing from you if you have already published or intend to publish your work.

Lets get in Touch
Filter by publishing year

  • Targeting BCMA in multiple myeloma with a trifunctional NK cell engager

    Alexandre Tang, Laurent Gauthier et al.. Cell reports Medicine 17 March 2026; 7(3).

    doi.org/10.1016/j.xcrm.2026.102628

  • Paratope mapping of tilvestamab, an anti-AXL function-blocking antibody, using high-throughput bacterial expression of secreted scFv-osmY fusion proteins

    Eleni Christakou, Petri Kursula et al.. Biosci Rep. 30 September 2025; 45(10): 635-647.

    doi.org/10.1042/bsr20253747

  • Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism

    Ronal M. Peralta, Bingxian Xie et al.. Nature Immunology 01 December 2024; 25(12): 2297-2307.

    doi.org/10.1038/s41590-024-01999-3

  • A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice

    Aman Mebrahtu, Ida Laurén et al.. Nature Communications 01 December 2024; 15(1).

    doi.org/10.1038/s41467-024-53839-5

  • Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

    Daouda Abba Moussa, Mario Vazquez et al.. Emerging Microbes & Infections 31 December 2024; 14(1).

    doi.org/10.1080/22221751.2024.2432345

  • Have you recently cited evitria in your publication? We would appreciate hearing from you if you have already published or intend to publish your work.

    Contact us

  • SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models

    Foram Dave, Poonam Vaghela et al.. Molecular Cancer Therapeutics 04 November 2024; 23(11): 1626-1638.

    doi.org/10.1158/1535-7163.mct-24-0187

  • A metabolic crosstalk between liposarcoma and muscle sustains tumor growth

    Gabrielle Manteaux, Alix Amsel et al.. Nature Communications 01 December 2024; 15(1).

    doi.org/10.1038/s41467-024-51827-3

  • A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

    Gerhard Frey, Ana Paula G. Cugnetti et al.. mAbs 31 December 2024; 16(1).

    doi.org/10.1080/19420862.2024.2322562

  • Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes

    Anna Zakrzewicz, Katrien Vanderheyden et al.. Frontiers in Immunology; 15.

    doi.org/10.3389/fimmu.2024.1473637

  • ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome

    Roeland Vanhauwaert, Julien Oury et al.. Science Translational Medicine 18 September 2024; 16(765).

    doi.org/10.1126/scitranslmed.ado7189

  • Identification of monoclonal antibodies from naive antibody phage-display libraries for protein detection in formalin-fixed paraffin-embedded tissues

    Célestine Mairaville, Morgane Broyon et al.. Journal of Immunological Methods; 532: 113730.

    doi.org/10.1016/j.jim.2024.113730

  • Skin Transcriptome Analysis Reveals Potential Molecular Mechanisms of S100A9 in Exacerbating the Inflammation in Rosacea

    Boyi Yang, Xiaopeng Ma et al.. Journal of Investigative Dermatology 01 December 2024; 144(12): 2812-2816.

    doi.org/10.1016/j.jid.2024.05.024

  • Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

    Hwai Wen Chang, Jing Wang et al.. Antibody Therapeutics 28 March 2025; 8(2): 145-156.

    doi.org/10.1093/abt/tbaf006

  • A blocking antibody against anti-Müllerian hormone restores ovulation and normal androgen levels in a spontaneous rat model of polycystic ovary syndrome

    Chrystèle Racine, François Fraissinet et al.. eBioMedicine; 115: 105716.

    doi.org/10.1016/j.ebiom.2025.105716

  • Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC

    Philipp Probst, Isabella Attinger-Toller et al.. Molecular Cancer Therapeutics 04 June 2025; 24(6): 803-815.

    doi.org/10.1158/1535-7163.mct-24-0983
Currently displaying: 15 / 122 publications